Model
Digital Document
Publisher
Florida Atlantic University
Description
Hepatocellular carcinoma is currently one of the most fatal cancers in the world. The routine treatment for this type of cancer consists of surgery, chemotherapy, and finally radiation therapy. Recent advancements in technology have enabled us to deliver highly conformed dose to planning target volume. Two of these methods are Intensity modulated Radiation Therapy (IMRT) and Stereotactic Body Radiation Therapy (SBRT). The difference between these two methods is that in the SBRT high radiation dose per fraction is delivered, but smaller number of fractions which renders better tumor control probability. However, better tumor control comes at the price of complications and radiation induced liver damage.
In this work, we compare the outcome of radiation with regards to the probability of radiation damage to the liver after IMRT and SBRT. For this purpose, we analyzed 10 anonymized patients’ data with liver cancer, and we made two similar treatment plans for them. The difference in two plans is dose per fraction and total dose. After optimizing the treatments and calculating the dose volume histogram, we found the effective volume of the liver being irradiated. Finally, this effective volume and the corresponding dose were used to show that SBRT has the advantage of better tumor control probability at the cost of higher probability of complications.
In this work, we compare the outcome of radiation with regards to the probability of radiation damage to the liver after IMRT and SBRT. For this purpose, we analyzed 10 anonymized patients’ data with liver cancer, and we made two similar treatment plans for them. The difference in two plans is dose per fraction and total dose. After optimizing the treatments and calculating the dose volume histogram, we found the effective volume of the liver being irradiated. Finally, this effective volume and the corresponding dose were used to show that SBRT has the advantage of better tumor control probability at the cost of higher probability of complications.
Member of